Coherence in amalgamated algebra along an ideal

Let $f: A\rightarrow B$ be a ring homomorphism and let $J$ be an ideal of $B$. In this paper, we investigate the transfert of the property of coherence to the amalgamation $A\bowtie^{f}J$. We provide necessary and sufficient conditions for $A\bowtie^{f}J$ to be a coherent ring

The susceptibility of Escherichia coli strains to essential oils of Rormarinus officinalis and Eucalyptus globulus

Essential oils are frequently used for flavour and fragrance in the perfume, pharmaceutical, cosmetic and food industries. They are also suitable raw material for production of new synthetic agents. The antibacterial activity of the essential oils obtained by steam distillation of Rosmarinus officinalis L and Eucalyptus globules collected in south Morocco was studied by micro-atmospheric technique against Escherichia coli CIP54127 and E. coli isolated from urine and resistant to several antibiotics. Both essential oils were effective against the two strains bacteria in particularly against E. coli CIP54127. MIQ of both oils ranged from 60 to 70 ìl for both bacteria. In conclusion, results show that essential oils are effective and could be considered as a natural antimicrobial source that can be used on production of natural antimicrobial agents

Toxicity of south Morocco Rosmarinus officinalis essential oil: antibacterial and histopathological effects

Le romarin (Rosmarinus officinalis) possède de nombreuses propriétés médicinales. Il est connu pour ses effets antimicrobiens et anti-oxydatifs. Le but de ce travail est d’étudier la toxicité de son huile essentielle (HE) via un test antibactérien selon la technique de micro-atmosphère et un autre histopathologique au niveau des organes de souris (Swiss albinos). L’analyse de la composition chimique de cette HE a été effectuée par CPG. Les constituants majoritaires de l’HE de R. officinalis sont le 1,8-cinéole (42%), l’alpha-pinène (11,92%) et le camphre (13.99%). Les quantités minimales inhibitrices des souches bactériennes testées varient entre 40 ?l et 90 ?l. Au plan histopathologique, une dilatation des alvéoles pulmonaires et une hypertrophie des cellules corticales et médullaires des surrénales ont été relevées. En conclusion, l’HE de R. officinalis ne présente pas de toxicité à la dose 50 ?l/g mais possède des effets stimulants des glandes surrénales et du système respiratoire

Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries

<p>Abstract</p> <p>Background</p> <p>In order to facilitate multinational clinical research, regulatory requirements need to become international and harmonised. The EU introduced the Directive 2001/20/EC in 2004, regulating investigational medicinal products in Europe.</p> <p>Methods</p> <p>We conducted a survey in order to identify the national regulatory requirements for major categories of clinical research in ten European Clinical Research Infrastructures Network (ECRIN) countries-Austria, Denmark, France, Germany, Hungary, Ireland, Italy, Spain, Sweden, and United Kingdom-covering approximately 70% of the EU population. Here we describe the results for regulatory requirements for typical investigational medicinal products, in the ten countries.</p> <p>Results</p> <p>Our results show that the ten countries have fairly harmonised definitions of typical investigational medicinal products. Clinical trials assessing typical investigational medicinal products require authorisation from a national competent authority in each of the countries surveyed. The opinion of the competent authorities is communicated to the trial sponsor within the same timelines, i.e., no more than 60 days, in all ten countries. The authority to which the application has to be sent to in the different countries is not fully harmonised.</p> <p>Conclusion</p> <p>The Directive 2001/20/EC defined the term 'investigational medicinal product' and all regulatory requirements described therein are applicable to investigational medicinal products. Our survey showed, however, that those requirements had been adopted in ten European countries, not for investigational medicinal products overall, but rather a narrower category which we term 'typical' investigational medicinal products. The result is partial EU harmonisation of requirements and a relatively navigable landscape for the sponsor regarding typical investigational medicinal products.</p

Ortholog of the polymerase theta helicase domain modulates DNA replication in Trypanosoma cruzi

DNA polymerase theta (Polθ), a member of the DNA polymerase family A, exhibits a polymerase C-terminal domain, a central domain, and an N-terminal helicase domain. Polθ plays important roles in DNA repair via its polymerase domain, regulating genome integrity. In addition, in mammals, Polθ modulates origin firing timing and MCM helicase recruitment to chromatin. In contrast, as a model eukaryote, Trypanosoma cruzi exhibits two individual putative orthologs of Polθ in different genomic loci; one ortholog is homologous to the Polθ C-terminal polymerase domain, and the other is homologous to the Polθ helicase domain, called Polθ-polymerase and Polθ-helicase, respectively. A pull-down assay using the T. cruzi component of the prereplication complex Orc1/Cdc6 as bait captured Polθ-helicase from the nuclear extract. Orc1/Cdc6 and Polθ-helicase directly interacted, and Polθ-helicase presented DNA unwinding and ATPase activities. A T. cruzi strain overexpressing the Polθ-helicase domain exhibited a significantly decreased amount of DNA-bound MCM7 and impaired replication origin firing. Taken together, these data suggest that Polθ-helicase modulates DNA replication by directly interacting with Orc1/Cdc6, which reduces the binding of MCM7 to DNA and thereby impairs the firing of replication origins